Rudwaleit, M, Landewe, Rene, Listing, J, Brandt, J, Braun, J, ...
Objective: Non-radiographic axial spondyloarthritis (SpA) is characterised by a lack of definitive radiographic sacroiliitis and is considered an early stage of ankylosing spondylitis. The objective...
Rudwaleit, M, Landewe, R, Listing, J, Akkoc, N, Brandt, J, ...
Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA). Methods: All assessment of SpondyloArthritis international Society...
Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., Sieper, J., ...
Objectives. Anti-tumour necrosis factor therapy with infliximab has been shown to improve signs and symptoms of patients with active ankylosing spondylitis (AS). The objective of this article was to...
Baraliakos, X, Brandt, J, Listing, J, Haibel, H, Rudwaleit, HM, Sieper, J, ...
No abstract available.
Baraliakos, X, Brandt, J, Listing, J, Sieper, J, Braun, J
No abstract available.
Baraliakos, X, Listing, J, Brandt, J, Rudwaleit, M, Sieper, J, Braun, J
No abstract available.
Baraliakos, X, Listing, J, Rudwaleit, M, Brandt, J, Sieper, J, Braun, J
No abstract available.
Brandt, J., Listing, J., Haibel, H., Sörensen, H., Schwebig, A., Rudwaleit, M., ...
Objectives. Treatment of ankylosing spondylitis (AS) with the tumour necrosis factor α (TNF-α) receptor fusion protein etanercept has shown efficacy in patients with active disease in randomized...
Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...
Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...
Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...
Sieper, J., Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., ...
Objectives. Patients with ankylosing spondylitis (AS) benefit from anti-TNF therapy both on a clinical basis and as depicted by magnetic resonance imaging (MRI). It is not known whether spinal...
Sieper, J., Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., ...
Objectives. Patients with ankylosing spondylitis (AS) benefit from anti-TNF therapy both on a clinical basis and as depicted by magnetic resonance imaging (MRI). It is not known whether spinal...
Brandt, J., Listing, J., Haibel, H., Sörensen, H., Schwebig, A., Rudwaleit, M., ...
Objective. Treatment of ankylosing spondylitis (AS) with the tumour necrosis factor α (TNF-α) receptor fusion protein etanercept has shown efficacy in patients with active disease in randomized...
Brandt, J., Listing, J., Haibel, H., Sörensen, H., Schwebig, A., Rudwaleit, M., ...
Objective. Treatment of ankylosing spondylitis (AS) with the tumour necrosis factor α (TNF-α) receptor fusion protein etanercept has shown efficacy in patients with active disease in randomized...
Zink, A, Listing, J, Niewerth, M, Zeidler, H
OBJECTIVE—To describe current treatment of patients with rheumatoid arthritis (RA) in German rheumatology. METHODS—Data from the German rheumatological database of 1998, comprising clinical...
Zink, A, Listing, J, Klindworth, C, Zeidler, H
OBJECTIVE—To describe the aims, principles, and content of the German rheumatological database and to present data on patient mix and healthcare provision for the year 1998. METHODS—The German...
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
Rudwaleit, M, Andermann, B, Alten, R, Sorensen, H, Listing, J, Zink, A, ...
Background: The prevalence of atopic disorders in ankylosing spondylitis (AS) is unknown. AS and rheumatoid arthritis (RA) exhibit divergent T helper (Th) cell cytokine patterns.
Rudwaleit, M, Listing, J, Brandt, J, Braun, J, Sieper, J
Background: TNFα blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS).
Burden and cost of illness in patients with juvenile idiopathic arthritis
Minden, K, Niewerth, M, Listing, J, Biedermann, T, Schontube, M, Zink, A
Objective: To estimate the cost of illness in an incidence based cohort of patients with juvenile idiopathic arthritis.
Braun, J, Baraliakos, X, Golder, W, Hermann, K, Listing, J, Brandt, J, ...
Objectives: To compare conventional radiography and magnetic resonance imaging (MRI) for detection of chronic changes in the spine of patients with ankylosing spondylitis (AS).
Brandt, J, Listing, J, Sieper, J, Rudwaleit, M, Braun, J
Objective: To develop and compare candidate improvement criteria for anti-TNFα treatment in ankylosing spondylitis with optimal discriminating capacity between treatment and placebo.
Listing, J, Brandt, J, Rudwaleit, M, Zink, A, Sieper, J, Braun, J
Methods: The data of a 2 year open extension study of a 12 week, double blind, randomised, placebo controlled trial, in which all patients with AS were treated with 5 mg/kg infliximab, were used to...
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Haibel, H, Rudwaleit, M, Listing, J, Sieper, J
Methods: Anakinra (100 mg) was given subcutaneously daily over 24 weeks to 20 NSAID refractory patients with ankylosing spondylitis. Thirteen completed the study. Clinical outcome assessments...
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
Braun, J, Brandt, J, Listing, J, Zink, A, Alten, R, Burmester, G, ...
Objective: To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal...
Baraliakos, X, Landewe, R, Hermann, K, Listing, J, Golder, W, Brandt, J, ...
Background: Magnetic resonance imaging (MRI) is increasingly used to detect inflammation in the spine of patients with ankylosing spondylitis (AS).
Baraliakos, X, Hermann, K, Landewe, R, Listing, J, Golder, W, Brandt, J, ...
Objectives: To compare the performance of two different MRI sequences—T1 weighted, fat saturated, spin echo after application of contrast medium, and short τ inversion recovery (STIR)...
Rudwaleit, M, Baraliakos, X, Listing, J, Brandt, J, Sieper, J, Braun, J
Objective: To assess the changes in inflammatory lesions of the spine and the sacroiliac (SI) joints as detected by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS) and...
Treatment continuation in patients receiving biological agents or conventional DMARD therapy
Zink, A, Listing, J, Kary, S, Ramlau, P, Stoyanova-Scholz, M, Babinsky, K, ...
Objective: To compare drug continuation rates in patients with rheumatoid arthritis who start on a biological agent and in a control group of patients with a change in disease modifying antirheumatic...
Baraliakos, X, Listing, J, Rudwaleit, M, Brandt, J, Sieper, J, Braun, J
Background: Anti-tumour necrosis factor (TNF) treatment is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by...